TY - JOUR
T1 - High Availability of the a7-Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment
T2 - A Pilot Study Using 18F-ASEM PET
AU - Coughlin, Jennifer M.
AU - Rubin, Leah H.
AU - Du, Yong
AU - Rowe, Steven P.
AU - Crawford, Jeffrey L.
AU - Rosenthal, Hailey B.
AU - Frey, Sarah M.
AU - Marshall, Erica S.
AU - Shinehouse, Laura K.
AU - Chen, Allen
AU - Speck, Caroline L.
AU - Wang, Yuchuan
AU - Lesniak, Wojciech G.
AU - Minn, Il
AU - Bakker, Arnold
AU - Kamath, Vidyulata
AU - Smith, Gwenn S.
AU - Albert, Marilyn S.
AU - Azad, Babak Behnam
AU - Dannals, Robert F.
AU - Horti, Andrew
AU - Wong, Dean F.
AU - Pomper, Martin G.
N1 - Publisher Copyright:
© 2020 Society of Nuclear Medicine Inc.. All rights reserved.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Emerging evidence supports a hypothesized role for the α7-nicotinic acetylcholine receptor (α7-nAChR) in the pathophysiology of Alzheimer's disease. 18F-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-18F-fluorodibenzo[b,d]thiophene 5,5-dioxide) is a radioligand for estimating the availability of α7-nAChR in the brain in vivo with PET. Methods: In this cross-sectional study, 14 patients with mild cognitive impairment (MCI), a prodromal stage to dementia, and 17 cognitively intact, elderly controls completed 18F-ASEM PET. For each participant, binding in each region of interest was estimated using Logan graphical analysis with a metabolite-corrected arterial input function. Results: Higher 18F-ASEM binding was observed in MCI patients than in controls across all regions, supporting higher availability of α7-nAChR in MCI. 18F-ASEM binding was not associated with verbal memory in this small MCI sample. Conclusion: These data support use of 18F-ASEM PET to examine further the relationship between α7-nAChR availability and MCI.
AB - Emerging evidence supports a hypothesized role for the α7-nicotinic acetylcholine receptor (α7-nAChR) in the pathophysiology of Alzheimer's disease. 18F-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-18F-fluorodibenzo[b,d]thiophene 5,5-dioxide) is a radioligand for estimating the availability of α7-nAChR in the brain in vivo with PET. Methods: In this cross-sectional study, 14 patients with mild cognitive impairment (MCI), a prodromal stage to dementia, and 17 cognitively intact, elderly controls completed 18F-ASEM PET. For each participant, binding in each region of interest was estimated using Logan graphical analysis with a metabolite-corrected arterial input function. Results: Higher 18F-ASEM binding was observed in MCI patients than in controls across all regions, supporting higher availability of α7-nAChR in MCI. 18F-ASEM binding was not associated with verbal memory in this small MCI sample. Conclusion: These data support use of 18F-ASEM PET to examine further the relationship between α7-nAChR availability and MCI.
KW - 18F-ASEM
KW - PET
KW - cholinergic
KW - dementia
KW - nAChR
UR - http://www.scopus.com/inward/record.url?scp=85081117280&partnerID=8YFLogxK
U2 - 10.2967/JNUMED.119.230979
DO - 10.2967/JNUMED.119.230979
M3 - Article
C2 - 31420499
AN - SCOPUS:85081117280
SN - 0161-5505
VL - 61
SP - 423
EP - 426
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 3
ER -